Unaudited, preliminary net revenue for the second quarter 2019 is expected to be in the range of $4.4 million to $4.7 million compared to $3.6 million in the second quarter of 2018. Second quarter 2019 international net revenue is expected to be in the range of $3.4 million to $3.6 million and United States net revenue is expected to be in the range of $1.0 million to $1.1 million. As of June 30, 2019, cash and cash equivalents are estimated to be approximately $65 million. Cash used in operating activities in the second quarter of 2019 was higher than in the first quarter of 2019, primarily driven by the timing of receivables collections within the year and inventory build for sales in the second half of 2019. "We are pleased with the progress our team has made in the U.S. since introducing the Bridge Patient Access Program. We have seen utilization increase, which reinforces the clinical value that the Eversense(R) CGM System provides to patients and the broader healthcare system," said Tim Goodnow, President and Chief Executive Officer of Senseonics. "Patient demand is strong, and we are successfully accelerating shipments and prescriptions globally, thus increasing our confidence in greater adoption of Eversense in the second half of the year."
